Activation of FcRn Mediates a Primary Resistance Response to Sorafenib in Hepatocellular Carcinoma by Single-Cell RNA Sequencing

• Main Authors: Xin Guan (Author), Yi Wu (Author), Shuqin Zhang (Author), Zhiyi Liu (Author), Qingjie Fan (Author), Shuai Fang (Author), Sennan Qiao (Author), Fei Sun (Author), Chongyang Liang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Sorafenib is the first-line therapeutic option for advanced hepatocellular carcinoma (HCC). Many patients exhibit a primary resistance (PR) response after initial treatment. In previous studies, compared to acquired resistance, the mechanism of PR is unclear. The present study aimed to evaluate the...